Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | FECH | P22830 | 1/20 | 0.32 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.32 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.32 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.32 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.32 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.32 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.32 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017835 | 0.88 | — | — | |
| SCHEMBL1129116 | 0.80 | TNK2 (0.46) | TNK2 | |
| SCHEMBL1129114 | 0.80 | TNK2 (0.46) | TNK2 | |
| SCHEMBL1758849 | 0.77 | TNK2 (0.42) | TNK2 | |
| SCHEMBL12017838 | 0.77 | TNK2 (0.42) | TNK2 | |
| SCHEMBL1131683 | 0.75 | TNK2 (0.53) | TNK2RIPK2RETNQO2CSNK2A2 | |
| SCHEMBL1129312 | 0.75 | PDE9A (0.30) | — | |
| SCHEMBL31391110 | 0.65 | TNK2 (0.48) | TNK2RIPK2RETNQO2CSNK2A2 | |
| SCHEMBL20874792 | 0.62 | CHRNA7 (0.33) | — | |
| SCHEMBL12006361 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011060112-A1 | DEUTERATED TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060112-A1 | DEUTERATED TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | TNK2 2837/4885RIPK2 3559/4885RET 153/4885 |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | IGF1R, INSR, IRS1 | TNK2 552/4885RIPK2 1390/4885RET 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.